Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1

AIDS Research and Human Retroviruses

Volumn 13, Issue 11, 1997, Pages 913-922

  Dunn, C S ^a   Hurtrel, B ^b   Beyer, C ^a   Gloeckler, L ^a   Ledger, T N ^a   Moog, C ^a   Kieny, M P ^c   Mehtali, M ^c   Schmitt, D ^c   Gut, J P ^a   Kirn, A ^a   Aubertin, A M ^a  

^a INSERUM U74   (France)

^b INSTITUT PASTEUR   (France)

^c TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMIAN IMMUNODEFICIENCY VIRUS; SUPERINFECTION; VIRUS EXPRESSION;

EID: 0030740438     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.913     Document Type: Article

References (53)

1. Haase AT: Pathogenesis of lentivirus infections. Nature (London) 1986;322:130-136.
2. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, and Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
3. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, and Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
4. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 1993;362:355-358.
5. Paul WE: Can the immune response control HIV infection? Cell 1995;82:177-182.
6. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
7. Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW, and Desrosiers RC: Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol 1987;68:3183-3189.
8. Zhang J, Martin LN, Warson EA, Montelaro RC, West M, Epstein L, and Murphy-Corb M: Simian immunodeficiency virus/Delta-induced immunodeficiency disease in rhesus monkeys: Relation of antibody response and antigenemia. J Infect Dis 1988:158:1277-1286.
9. Kestler HW, Kodama T, Ringler DJ, Marthas M, Pederson NC, Lackner A, Reiger D, Seghal PK, Daniel MD, King NW, and Desrosiers RC: Induction of AIDS in rhesus monkeys by molecularly cloned simiam immunodeficiency virus. Science 1990;248:1109-1112.
10. Venet A, Bourgault I, Aubertin AM, Kieny MP, and Levy JP: Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques. J Immunol 1992;148:2899-2908.
11. Lewis MG, Bellah S, McKinnon K, Yalley-Ogunro J, Zack PM, Elkins WR, Desrosiers RC, and Eddy GA: Titration and characterisation of two rhesus-derive SIVmac challenge stocks. AIDS Res Hum Retroviruses 1994;10:213-220.
12. Hoch J, Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Dittmer U, Hunsmann G, Fuchs D, Muller J, Sopper S, Fleckenstein B, and Uberla KT: vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol 1995;69:4807-4813.
13. Perryman LE, O'Rourke KI, and McGuire TC: Immune responses are required to terminate viraemia in equine infectious anaemia lentivirus infection. J Virol 1988;62:3073-3076.
14. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb KE, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-624.
15. Fultz PN, Nara P, Barre-Sinoussi F, Chaput A, Greenbert ML, Muchmore E, Kieny MP, and Girard M: Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-1690.
16. Hu S-L, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller LR, Morton WR, and Beneveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
17. Stott EJ: Towards a vaccine against AIDS: Lessons from simian immunodeficiency virus vaccines. In: Simian Immunodeficiency Virus: Current Trends in Immunology and Microbiology (Letvin NL and Desrosiers RC, eds.), Vol 188. Springer Verlag, Berlin, New York, 1994, pp. 221-237.
18. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, and Desrosiers RC: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65:651-662.
19. Daniel MD, Kirschhoff F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
20. Almond N, Kent K, Cranage M, Rud E, Clarke B, and Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995; 345:1342-1344.
21. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, and Biberfeld G: Infection of cynomologus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990; 4:783-789.
22. Putkonen P, Walther L, Zhang YJ, Li SL, Nilsson C, Albert J, Biberfeld P, Thorstensson R, and Biberfeld G: Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med 1995;1:914-918.
23. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, and Pedersen NC: Immunization with a live, attenuated simian immunodeficiency virus prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 1990;64:3694-3700.
24. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, and Adachi A: Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol 1991;65:3314-3520.
25. Sakuragi S, Shibata R, Mukai R, Komatsu T, Fukasawa M, Sakai H, Sakuragi JI, Kawamura M, Ibuki K, Hayami M, and Adachi A: Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J Gen Virol 1992;73:2983-2987.
26. Li J, Lord CI, Haseltine W, Letvin NL, and Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 glycoproteins. J Acquire Immune Defic Syndr 1992;5:639-646.
27. Igarashi T, Shibata R, Hasebe F, Ami Y, Shinohara K, Komatsu T, Stahl-Hennig C, Petry H, Hunsmann G, Kuwata T, Jin M, Adachi A, Kurimura T, Okada M, Miura T, and Hayami M: Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Hum Retroviruses 1994;10:1021-1029.
28. Luciw PA, Pratt-Lowe E, Shaw KES, Levy JA, and Cheng-Meyer C: Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995;92:7490-7494.
29. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, Letvin NL, and Sodroski JG: Persistent infection of macaques with simian-human immunodeficiency virus. J Virol 1995;69:7061-7071.
30. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B, and Sodroski J: Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci 1995;92:8210-8214.
31. Dunn CS, Beyer C, Kieny MP, Gloeckler L, Schmitt D, Gut JP, Kirn A, and Aubertin AM: High viral load and CD4 lymphopenia in rhesus and cynomologus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat and vpu genes from HIV-1 Lai. Virology 1996;223:351-361.
32. Stott EJ, Almond N, Kent KA, Chan WL, Cranage MP, Kitchin PA, Mills KHG, Page M, and Rud E: Animal models in the development of AIDS vaccines. In: Retroviruses of Human AIDS and Related Animal Diseases (Girard M and Valette L, eds.). 8th Cent Gardes Meeting, Marnes-la-Coquette, France. Fondation Marcel Mérieux, Lyon, France, 1993, pp. 131-137.
33. Stott EJ, Almond N, West W, Kent K, Cranage MP, and Rud E: Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. In: Retroviruses of Human AIDS and Related Animal Diseases (Girard M and Valette L, eds.). 9th Cent Gardes Meeting, Marnes-la-coquette, France. Fondation Marcel Mérieux, Lyon, France, 1994, pp. 219-224.
34. Letvin NL, Li J, Halloran L, Cranage MP, Rud EW, and Sodroski J: Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus. J Virol 1995:69:4569-4571.
35. Bogers WMJM, Niphuis H, ten Haaft P, Laman JD, Koornstra W, and Heeney JL: Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge. AIDS 1995;9:F13-F18.
36. Council directive on the protection of animals used for experimental and other scientific purposes. 86/609/EEC, Journal Officiel des Communautés Européennes, L358, December 18, 1986.
37. Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, Burny A, Fultz PN, Mullins JI, and Hoover EA: Incomplete protection but suppression of viras burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68:1843-1853.
38. Regier DA and Desrosiers RC: The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:1221-1231.
39. Moog C, Wick A, Le Ber P, Kirn A, and Aubertin AM: Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus. Antiviral Res 1994;24:275-288.
40. Spouge JL: Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci USA 1992;89:7581-7585.
41. Moog C, Spenlehauer C, Fleury H, Heshmati F, Saragosti S, Letourneur F, Kirn A, and Aubertin AM: Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neuralization in vitro. AIDS Res Hum Retrovirases 1997;13:19-27.
42. Ou CY, Kwok S, Mitchell SW, Mack DH, Sninsky JT, Krebs JW, Feorino P, Warfield D, and Schochetman G: DNA amplification for direct detection of HIV-1 in DNA of peripheral mononuclear cells. Science 1988;239:295-297.
43. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, and Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996;70:3724-3733.
44. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, Hellinger J, Ndiaye-Guèye A, Sankalé JL, Ndoye I, Mboup S, and Essex M: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1990.
45. Travers K, Mboup S, Marlink R, Guèye-Ndiaye A, Siby T, Thior I, Traore I, Dieng-Sarr A, Sankalé JL, Mullins C, Ndoye I, Hsieh CC, Essex M, and Kanki P: Natural protection against HIV-1 infection provided by HIV-2. Science 1995;268:1612-1615.
46. Rowland-Jones S, Sutton J, Ariyosho K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, and Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1:59-64.
47. Van Rompay KKA, Ostyula MG, Tarra RP, Canfield DR, Berardi CJ, McChesney MB, and Marthas ML: Vaccination of pregnant macaques protects newboms against mucusal simian immunodeficiency virus infection. J Infect Dis 1996;173:1327-1335.
48. Letvin NL: Vaccines against human immunodeficiency virus - progress and prospects. New Engl J Med 1993;329:1400-1405.
49. Johnson PR, Trocha A, Buchanan TM, and Walker BD: J Virol 1993;67:438-445.
50. Carmichael A, Jin X, and Sissions P: Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency viras type 1 infection: Low prevalence of broadly cross-reactive env-specific CTL. J Virol 1996;70:8468-8474.
51. Petry H, Dittmer U, Stahl-Hennig C, Coulibaly C, Makoschey B, Fuchs D, Wachter H, Tolle T, Morys-Wortmann C, Kaup FJ, Jurkiewicz E, Luke W, and Hunsmann G: Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection. J Virol 1995;69:1564-1574.
52. Clerici M, Clark EA, Polacino P, Axberg I, Kuller L, Casey NI, Morton WR, Shearer GM, and Benveniste RE: T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 1994;8:1391-1395.
53. Dittmer U, Stahl-Hennig C, Coulibaly C, Nisslein T, Luke W, Fuchs D, Bodemer W, Petry H, and Hunsmann G: Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against consequences of a high-dose challenge. J Gen Virol 1995;76:1307-1315.